SCHEMBL1065723

SCHEMBL1065723

CCOC(=O)/C=C(\C)Oc1ccccc1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.40
KMT2A Q03164 4/20 0.40
KDM4E B2RXH2 4/20 0.40
RAB9A P51151 4/20 0.40
POLB P06746 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
PKM P14618 1/20 0.40
GALK1 P51570 1/20 0.40
CCR6 P51684 1/20 0.40
BLM P54132 1/20 0.40
MCL1 Q07820 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
MEN1 O00255 3/20 0.39
ATM Q13315 1/20 0.39
LMNA P02545 3/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1065726 1.00 MAPT (0.40) MAPTKMT2AKDM4ERAB9APOLB
SCHEMBL1065729 1.00 MAPT (0.40) MAPTKMT2AKDM4ERAB9APOLB
SCHEMBL1065610 0.86 TDP1 (0.46) MAPTKMT2AKDM4ERAB9APOLB
SCHEMBL1065614 0.86 TDP1 (0.46) MAPTKMT2AKDM4ERAB9APOLB
SCHEMBL1065611 0.86 TDP1 (0.46) MAPTKMT2AKDM4ERAB9APOLB
SCHEMBL1066297 0.86 MAPT (0.35) MAPTKMT2AKDM4ERAB9APOLB
SCHEMBL1066298 0.86 MAPT (0.35) MAPTKMT2AKDM4ERAB9APOLB
SCHEMBL1066301 0.86 MAPT (0.35) MAPTKMT2AKDM4ERAB9APOLB
SCHEMBL1063648 0.84 MAPT (0.48) MAPTKMT2AKDM4ERAB9APOLB
SCHEMBL11820242 0.84 MAPT (0.46) MAPTKMT2AKDM4ERAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 MAPT 4151/4885KMT2A 2072/4885KDM4E 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.